ABBOTT LABORATORIES (NYSE:ABT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Election of Directors
On June29, 2017, John G. Stratton was named to the Abbott
Laboratories Board of Directors, effective immediately.
Item 5.03 Amendments to Articles of Incorporation or
Bylaws; Change in Fiscal Year
On June28, 2017, Abbotts Board of Directors amended the first
sentence of ArticleIII, Section2 of Abbotts by-laws to provide
that Abbotts Board of Directors shall consist of twelve persons,
effective as of June29, 2017. Abbotts by-laws previously provided
that the Board of Directors consisted of eleven persons.
Item 9.01 Financial Statements and
Exhibits
|
ExhibitNo. |
|
Exhibit |
|
3.1 |
By-Laws of Abbott Laboratories, as amended and restated |
ABBOTT LABORATORIES ExhibitEX-3.1 2 a17-15898_1ex3d1.htm EX-3.1 Exhibit 3.1 BY-LAWS OF ABBOTT LABORATORIES Adopted by the Board of Directors of Abbott Laboratories at the Annual Meeting,…To view the full exhibit click here About ABBOTT LABORATORIES (NYSE:ABT)
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Nutrition Products segment includes the sales of a line of adult and pediatric nutritional products. The Diagnostic Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.
